675 related articles for article (PubMed ID: 18042229)
1. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse.
Freitag FG; Diamond S; Diamond M; Urban G
Headache; 2008 Feb; 48(2):201-9. PubMed ID: 18042229
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
Shuhendler AJ; Lee S; Siu M; Ondovcik S; Lam K; Alabdullatif A; Zhang X; Machado M; Einarson TR
Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine.
Blumenfeld AM; Schim JD; Chippendale TJ
Headache; 2008 Feb; 48(2):210-20. PubMed ID: 18047502
[TBL] [Abstract][Full Text] [Related]
7. Duration of migraine is a predictor for response to botulinum toxin type A.
Eross EJ; Gladstone JP; Lewis S; Rogers R; Dodick DW
Headache; 2005 Apr; 45(4):308-14. PubMed ID: 15836566
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study.
Evers S; Vollmer-Haase J; Schwaag S; Rahmann A; Husstedt IW; Frese A
Cephalalgia; 2004 Oct; 24(10):838-43. PubMed ID: 15377314
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin type A in prophylactic treatment of migraine.
Anand KS; Prasad A; Singh MM; Sharma S; Bala K
Am J Ther; 2006; 13(3):183-7. PubMed ID: 16772757
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study.
Schulte-Mattler WJ; Krack P;
Pain; 2004 May; 109(1-2):110-4. PubMed ID: 15082132
[TBL] [Abstract][Full Text] [Related]
11. Effect of preventive treatment with botulinum toxin type A on acute headache medication usage in migraine patients.
Schim J
Curr Med Res Opin; 2004 Jan; 20(1):49-53. PubMed ID: 14741072
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine.
Saper JR; Mathew NT; Loder EW; DeGryse R; VanDenburgh AM;
Pain Med; 2007 Sep; 8(6):478-85. PubMed ID: 17716321
[TBL] [Abstract][Full Text] [Related]
13. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches.
Relja M; Poole AC; Schoenen J; Pascual J; Lei X; Thompson C;
Cephalalgia; 2007 Jun; 27(6):492-503. PubMed ID: 17428299
[TBL] [Abstract][Full Text] [Related]
14. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
Mathew NT; Kailasam J; Meadors L
Headache; 2008 Feb; 48(2):194-200. PubMed ID: 17868356
[TBL] [Abstract][Full Text] [Related]
15. Botulinum toxin in migraine prophylaxis.
Göbel H
J Neurol; 2004 Feb; 251 Suppl 1():I8-11. PubMed ID: 14991336
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial.
Vo AH; Satori R; Jabbari B; Green J; Killgore WD; Labutta R; Campbell WW
Aviat Space Environ Med; 2007 May; 78(5 Suppl):B113-8. PubMed ID: 17547312
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin type A in chronic migraine.
Freitag FG
Expert Rev Neurother; 2007 May; 7(5):463-70. PubMed ID: 17492897
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine.
Magalhães E; Menezes C; Cardeal M; Melo A
Clin Neurol Neurosurg; 2010 Jul; 112(6):463-6. PubMed ID: 20399553
[TBL] [Abstract][Full Text] [Related]
19. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
[TBL] [Abstract][Full Text] [Related]
20. A prospective randomized controlled study of the role of botulinum toxin in whiplash-associated disorder.
Carroll A; Barnes M; Comiskey C
Clin Rehabil; 2008 Jun; 22(6):513-9. PubMed ID: 18511531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]